Description
Added on the 20/03/2021 13:00:00 - Copyright : EFE Inglés
Shanghai, Jan 4 (EFE/EPA).- Fosun Pharma, a Chinese listed pharmaceutical company, and Germany's BioNTech reported in December that they would supply Mainland China with 100 million doses of a COVID-19 vaccine in 2021, after regulatory approval. In March 2020, Shanghai-based pharmaceutical company Fosun Pharma made a purchase agreement with BioNTech to buy 50 million USD worth of stock. It became a strategic partner in developing and producing the mRNA vaccine. (Camera: ALEX PLAVEVSKI).SHOT LIST: THE FOSUN PHARMA HEADQUARTERS BUILDING IN SHANGHAI, CHINA.
On Wednesday, Pfizer and BioNTech announced having reached a deal with the U.S. government with an additional 100 million doses by July 31. That's up from the initial 100 million doses ordered already. The deal follows a similar extension of doses reached by the U.S. with Moderna for their vaccine. Both vaccines require two doses to be administered. The $2 billion deal calls for at least an additional 70 million doses to be provided to the U.S. by June 30. The remaining 30 million doses needing to be delivered by July 31. It also allows for the U.S. to obtain up to an additional 400 million doses in the future.